Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Quarterly Earnings Results

Recursion Pharmaceuticals (NASDAQ:RXRX) posted its quarterly earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08, FiscalAI reports. The firm had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The business’s revenue was down 56.8% compared to the same quarter last year. During the same period last year, the firm posted ($0.50) earnings per share.

Here are the key takeaways from Recursion Pharmaceuticals’ conference call:

• REC-4881: Company-reported clinical proof-of-concept in FAP showing significant reductions in precancerous polyps with durable responses, and ongoing FDA engagement to define a potential registrational path.
• REC-1245 (RBM39 degrader): Early DAHLIA Phase I data from 16 patients report no dose-limiting toxicities, PD-confirmed target engagement and PK supportive of daily dosing, with more dose-escalation and fuller PK/PD readouts expected in H2.
• REC-4539 (LSD1 inhibitor): First patient dosed in Phase I for a molecule designed to reduce thrombocytopenia risk and that is brain-penetrant; initial PK and safety data are expected in H2 2027.
• Platform and model advances (TxPert, TxFM) and company-reported efficiency claims — e.g., >50 PB of multimodal data, ~90% fewer compounds synthesized and ~2x faster progress to development candidates — are being deployed but remain company-reported metrics to be independently validated by future outcomes.
• Financial position: $665M in cash, asserted runway into early 2028, a 30% year-over-year reduction in operating expenses, and 2026 cash OpEx guidance under $390M, which management says funds near-term milestones without additional financing.

Recursion Pharmaceuticals Trading Up 1.3%

Shares of NASDAQ RXRX traded up $0.05 during mid-day trading on Wednesday, hitting $3.42. The stock had a trading volume of 14,705,881 shares, compared to its average volume of 16,692,518. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.50 and a current ratio of 5.50. Recursion Pharmaceuticals has a 1 year low of $2.80 and a 1 year high of $7.18. The business has a 50 day moving average price of $3.40 and a two-hundred day moving average price of $4.16. The firm has a market cap of $1.80 billion, a P/E ratio of -2.31 and a beta of 1.05.

Analyst Ratings Changes

Several research firms have commented on RXRX. JPMorgan Chase & Co. decreased their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th. Wall Street Zen downgraded shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Bank of America decreased their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $9.20.

Insider Buying and Selling

In related news, CEO Najat Khan sold 28,298 shares of Recursion Pharmaceuticals stock in a transaction on Monday, March 9th. The shares were sold at an average price of $3.35, for a total value of $94,798.30. Following the sale, the chief executive officer owned 2,262,085 shares in the company, valued at $7,577,984.75. The trade was a 1.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $3.10, for a total transaction of $93,000.00. Following the completion of the sale, the director owned 6,229,863 shares in the company, valued at approximately $19,312,575.30. This trade represents a 0.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 79,680 shares of company stock valued at $256,121 over the last three months. 8.43% of the stock is owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. NewEdge Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 28.1% during the 2nd quarter. NewEdge Advisors LLC now owns 11,061 shares of the company’s stock valued at $56,000 after buying an additional 2,428 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter valued at $61,000. Daiwa Securities Group Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 29.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,706 shares of the company’s stock valued at $64,000 after buying an additional 2,883 shares in the last quarter. Focus Partners Wealth bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $77,000. Finally, RPO LLC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $62,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.